 |
Twice-Weekly Briefing
Friday, November 13, 2026
Issue 261113-80
|
|
|
The MOC Brief
Health policy, priced and translated for self-funded plan sponsors
|
|
In This Edition
Five developments, and what each one costs you.
| 1. | FDA is requiring a new eye risk warning in the labeling of every approved GLP-1. | | 2. | A New York behavioral health settlement states that its relief does not reach self-funded ERISA plans. | | 3. | Benefits audits, transparent PBM pricing and data analytics all tied at 83 percent among employers' 2027 cost tactics. | | 4. | Two No Surprises Act arbitrators can no longer accept new disputes, with 30 business days to appeal. | | 5. | Google Cloud's new healthcare AI, in preview, lists payer benefit determination among its capabilities. |
|
|
| 1 · PHARMACY SAFETY · November 9, 2026 |
| FDA Is Requiring an Eye Risk Warning in the Labeling of Every Approved GLP-1 |
| On November 9, 2026 the Food and Drug Administration said it is requiring application holders for all GLP-1 receptor agonist medications to add information to the Warnings and Precautions section of labeling about a potential increased risk of non-arteritic anterior ischemic optic neuropathy, a rare and usually painless loss of vision in one eye. FDA pooled 126 randomized controlled trials covering 134,253 patients and 288,879 person-years and identified 15 probable cases, 10 among the 78,217 people taking a GLP-1 and 5 among the 56,036 taking a comparator, all five of those on placebo. That is 6.4 cases per 100,000 person-years on a GLP-1 against 3.8 on a comparator, inside a general population range FDA puts at 2.3 to 10.2 cases per 100,000 people a year in adults older than 50. A separate FDA cohort study of adults with type 2 diabetes from 2019 to 2024 found no statistically significant increase against SGLT-2 inhibitors, a hazard ratio of 1.19 with an interval of 0.91 to 1.54, and a significant one against DPP-4 inhibitors at 1.43, with an interval of 1.02 to 2.01. FDA calls this a potential increased risk rather than an established cause, says its review of the available animal data did not identify a mechanism, and tells prescribers to consider discontinuing a GLP-1 in patients who develop the condition unless the benefits clearly outweigh the risk. The agency's table lists twelve products, one of them withdrawn, among them Ozempic, Wegovy, Mounjaro and Zepbound. |
|
MOC Perspective
GLP-1s are the fastest growing line in most self-funded pharmacy budgets, so a class-wide labeling change reaches your plan in three places at once: prior authorization criteria, member communications, and the clinical review your vendor already performs. FDA's page says nothing about health plans, payers, coverage or formularies, so nothing here obliges you to change a benefit. What it changes is what your members will ask about and what your pharmacy vendor should already be screening for, and the absolute numbers are small enough that overcorrecting will cost you more than the risk is worth.
What to do now
| ▪ | Ask your pharmacy benefit vendor, before January 1, 2027, whether its GLP-1 prior authorization criteria screen for prior vision loss in one eye. | | ▪ | Pull your 2026 GLP-1 claim count and confirm which of the eleven marketed products on FDA's list your formulary covers. | | ▪ | Tell members on a GLP-1 to report sudden painless vision loss in one eye the same day, using FDA's own symptom wording. |
|
|
| Source: U.S. Food and Drug Administration, Drug Safety Communication, November 9, 2026 |
|
| 2 · BEHAVIORAL HEALTH ACCESS · November 10, 2026 |
| A New York Settlement Over a Behavioral Health Ghost Network Expressly Skips Self-Funded ERISA Plans |
| On November 10, 2026 New York Attorney General Letitia James announced two settlements with Carelon Behavioral Health, which the Attorney General's office says administers all behavioral health benefits for EmblemHealth, Anthem Blue Cross Blue Shield, Independent Health and the Empire Plan, and is responsible for the behavioral health coverage of more than four million New Yorkers. A secret shopper study the office ran found that 82 percent of the 44 surveyed Emblem behavioral health providers Carelon listed as accepting new patients were effectively unavailable. Carelon will pay $2.35 million in penalties, fees and costs, cap restitution for members who went out of network at $8 million in total, repay members sent to a wrongly listed provider in full with 12 percent interest and no cap, and overhaul its provider directories and its substance use disorder coverage reviews. The settlements decide no question of liability. The respondents "neither admit nor deny OAG's Findings, Paragraphs 1 through 49" in the first assurance, and neither admit nor deny the findings in the second, where the Attorney General's office found 41 instances of unapproved medical necessity criteria across roughly 7,900 denials between 2015 and 2022 and recorded that Carelon had earlier acknowledged 21 of them. Paragraph 70 of the first assurance then says, in its own words, that "The relief described in Paragraphs 71 through 97 below does not apply to self-funded plans governed by ERISA", while the same relief does apply to fully insured plans governed by ERISA. |
|
MOC Perspective
If your plan is self-funded, the first assurance tells you in a single sentence that none of its relief reaches your members. The directory rebuild and the restitution run to commercial, Essential Plan, Qualified Health Plan, Medicaid managed care, Child Health Plus and New York government employee business, and stop short of you. The corrected substance use disorder criteria sit in the second assurance, which carves out no plan type at all, so that is the one to ask about. Either way the diligence stays yours, and this study is a measurement of what a provider directory can actually be worth.
What to do now
| ▪ | Ask your behavioral health vendor in writing what share of its listed in-network providers accepted a new patient in the last 90 days. | | ▪ | Run your own secret shopper check on 25 listed behavioral health providers before your next renewal. | | ▪ | Compare your vendor's medical necessity criteria for substance use treatment against your state regulator's approved criteria within 60 days. |
|
|
| Source: New York Attorney General, settlements with Carelon Behavioral Health, November 10, 2026, with the Assurance of Discontinuance |
|
| 3 · BENEFITS STRATEGY · November 9, 2026 |
| Three Cost Tactics Tied at 83 Percent at the Top of Employers' 2027 List |
| Brown & Brown released its Employer Health and Benefits Strategy Survey, 2027 on November 9, 2026, drawn from "nearly 1,000 employers" with "at least 200 employees based in the US", fielded from July 21 through August 28, 2026, with a margin of error of plus or minus 3 percent. Just under half, 44 percent, named controlling health benefit costs for the organization their top priority, which the release says ranked "notably above" controlling health benefit costs for the employees. The top five cost containment strategies came in almost tied: benefits audits across claims, pharmacy and clinical at 83 percent, evaluating transparent PBM vendors or pricing models at 83 percent, stronger data analytics at 83 percent, evaluating medical stop-loss plan design at 82 percent, and medical or pharmacy RFPs at 82 percent. Forty-five percent cover GLP-1s for weight loss, and of those more than 77 percent restrict access, most often by setting clinical criteria tighter than FDA's, which 45 percent of that group do, or by requiring a lifestyle, behavior or weight management program, at 33 percent. Seventy-eight percent say well-being programs are part of their health care strategy and 79 percent of that group plan to raise those budgets, while 80 percent are prioritizing better access to behavioral health providers. |
|
MOC Perspective
Four of the five tactics at the top of that list are things you buy rather than things you decide: an audit, a PBM evaluation, an analytics build, a stop-loss review. The useful signal is the tie. When employers your size are all doing the same few things, the audit stops being a differentiator and the only question left is whether you act on what it finds. Read the figures for what they are, too: this asked employers in July and August what they plan to do, not what anything cost them.
What to do now
| ▪ | Price a claims and pharmacy audit before your 2027 renewal, and ask the vendor what it found for three clients your size. | | ▪ | Put your PBM contract's pricing model beside a transparent model quote this quarter. | | ▪ | Review your medical stop-loss specific deductible against your three largest claimants from 2026. |
|
|
| Source: Brown & Brown, Employer Health and Benefits Strategy Survey, 2027, company news release, November 9, 2026 |
|
| 4 · ARBITRATION OVERSIGHT · November 4, 2026 |
| Two Surprise Billing Arbitrators Can No Longer Take New Disputes While They Appeal the Decision |
| On November 4, 2026 the Departments of Health and Human Services, Labor and the Treasury announced they are denying recertification to two of the entities that arbitrate No Surprises Act payment disputes, Island Peer Review Organization, Inc., doing business as IPRO, and Network Medical Review Company, LLC. The Departments said both "failed to meet minimum performance standards required of certified IDR entities" and are "no longer eligible to accept new disputes under the Federal IDR process". The decision is not final yet: each has 30 business days from the date of the written recertification denial notice to request an appeal, and the Departments say they "will not issue a notice of final denial of recertification until the appeal period has elapsed". Parties with an open dispute before either entity "should expect further guidance from the Departments on next steps for their case". Eight other certified IDR entities have finished their public petition periods and are under review, and the Departments say this decision "does not affect the certification status of any other certified IDR entity". |
|
MOC Perspective
Your plan is a party to every IDR case your administrator files or answers, so a disqualified arbitrator becomes your problem whether or not your TPA raises it. If an open dispute of yours sat with IPRO or Network Medical Review, the Departments say only that you should expect further guidance on next steps, and the notice does not say when that arrives or what happens to the case meanwhile. The same notices page carries a second deadline worth your calendar: the IDR web forms leave the non-Gateway channel after January 15, 2027, with only the resubmission notice form still available outside it, and a party that uses a third-party administrator has to make sure that administrator signs up for an IDR Gateway account.
What to do now
| ▪ | Ask your TPA this week how many of your open IDR disputes sat with IPRO or Network Medical Review Company. | | ▪ | Confirm your third-party administrator has an IDR Gateway account before January 15, 2027. | | ▪ | Pull your 2026 IDR case count and award amounts, so you can price what restarting a disputed case would cost. |
|
|
| Source: Departments of Health and Human Services, Labor and the Treasury, Federal IDR notices page, November 4, 2026 |
|
| 5 · PAYER AI · November 10, 2026 |
| Google Cloud Put Payer Benefit Determination Into a Healthcare AI Now in Preview |
| Google Cloud launched Gemini for healthcare on November 10, 2026, describing it as "built around four core capabilities designed specifically for payers and providers" and as "Initially available in preview". The named capabilities include "payer benefit determination" and "coverage and policy review", while a partner integration called Infinitus Relay handles "automating benefit verification and supporting prior authorization workflows" and a UiPath integration "automates clinical chart summaries and extracts citation-backed evidence to accelerate utilization reviews and appeals". The named launch customers are Blue Cross Blue Shield of Massachusetts, Hartford HealthCare, HCA Healthcare, Highmark Health, Northwell Health, Optum and Stanford School of Medicine. Google credits outside bodies for the problem it says this addresses, citing 41.9 percent physician burnout from a 2025 American Medical Association report and administrative costs at "an estimated 25% to 35% of total U.S. healthcare spending" according to the American Hospital Association. The release never says whose coverage any of this runs on. It talks about payers and providers as categories, names no line of business anywhere, and the only government data it names is a feed of CMS coverage data. |
|
MOC Perspective
Two functions on that capability list are ones you delegate outright: deciding whether a benefit applies and reviewing coverage policy. Prior authorization shows up a step further out, in a partner integration. The announcement does not say whether any of it will reach employer business, because it does not describe lines of business at all. That silence is the thing to act on while the product is still in preview, so get your administrator's answer in writing now rather than learning about a change in coverage decision tooling after it is running on your claims.
What to do now
| ▪ | Ask your carrier or TPA in writing, before your next renewal, whether it is putting a general purpose AI model into benefit determination or prior authorization on your book. | | ▪ | Require 30 days' written notice of any change to the tooling used in your plan's coverage decisions, at your next contract amendment. | | ▪ | Pull your 2026 prior authorization denial and overturn counts now, so you hold a baseline to compare against. |
|
|
| Source: Google Cloud, press release announcing Gemini for healthcare, November 10, 2026 |
|
|
The Bottom Line
Four of these five stories are somebody else doing work on your plan: a drug maker relabeling, a vendor rebuilding a directory, an arbitrator losing its eligibility to take new cases, and a cloud company offering coverage decision tooling it has not said who will use. The line they all land on is delegation. Every one is a function a self-funded sponsor hands to someone else and keeps the legal duty for, and in two of the five the source document never names an employer plan at all. Asking costs nothing this month. The answers get expensive once a renewal is signed.
|
|
|
Jude Odu
Founder and Principal, Model Optimal Care
Author of Model Optimal Care: End U.S. Healthcare Waste, One Health Plan at a Time
|
|
|
|